304 related articles for article (PubMed ID: 34115836)
1. Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Haertle L; Barrio S; Munawar U; Han S; Zhou X; Vogt C; Fernández RA; Bittrich M; Ruiz-Heredia Y; Da Viá M; Zovko J; Garitano-Trojaola A; Bolli N; Ruckdeschel A; Stühmer T; Chatterjee M; Kull M; Krönke J; Agirre X; Martin-Subero JI; Raab P; Einsele H; Rasche L; Martinez-Lopez J; Haaf T; Kortüm KM
Blood; 2021 Nov; 138(18):1721-1726. PubMed ID: 34115836
[TBL] [Abstract][Full Text] [Related]
2. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.
Jones JR; Barber A; Le Bihan YV; Weinhold N; Ashby C; Walker BA; Wardell CP; Wang H; Kaiser MF; Jackson GH; Davies FE; Chopra R; Morgan GJ; Pawlyn C
Leukemia; 2021 Oct; 35(10):3017-3020. PubMed ID: 34373585
[No Abstract] [Full Text] [Related]
3. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
[TBL] [Abstract][Full Text] [Related]
4. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
5. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Gooding S; Ansari-Pour N; Kazeroun M; Karagoz K; Polonskaia A; Salazar M; Fitzsimons E; Sirinukunwattana K; Chavda S; Ortiz Estevez M; Towfic F; Flynt E; Pierceall W; Royston D; Yong K; Ramasamy K; Vyas P; Thakurta A
Blood; 2022 Oct; 140(16):1816-1821. PubMed ID: 35853156
[TBL] [Abstract][Full Text] [Related]
6. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Gooding S; Ansari-Pour N; Towfic F; Ortiz Estévez M; Chamberlain PP; Tsai KT; Flynt E; Hirst M; Rozelle D; Dhiman P; Neri P; Ramasamy K; Bahlis N; Vyas P; Thakurta A
Blood; 2021 Jan; 137(2):232-237. PubMed ID: 33443552
[TBL] [Abstract][Full Text] [Related]
7. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Borsi E; Mazzocchetti G; Dico AF; Vigliotta I; Martello M; Poletti A; Solli V; Armuzzi S; Taurisano B; Kanapari A; Pistis I; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Rocchi S; Rizzello I; Cavo M; Terragna C
Clin Exp Med; 2023 Dec; 23(8):5227-5239. PubMed ID: 37815734
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
9. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of cereblon expression in multiple myeloma.
Schuster SR; Kortuem KM; Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Ahmann G; Kumar S; Rajkumar SV; Mikhael J; Laplant B; Champion MD; Laumann K; Barlogie B; Fonseca R; Bergsagel PL; Lacy M; Stewart AK
Leuk Res; 2014 Jan; 38(1):23-8. PubMed ID: 24129344
[TBL] [Abstract][Full Text] [Related]
12. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
13. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
[TBL] [Abstract][Full Text] [Related]
14. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
15. Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.
Beedie SL; Huang PA; Harris EM; Strope JD; Mahony C; Chau CH; Vargesson N; Figg WD
FASEB J; 2020 Sep; 34(9):11395-11404. PubMed ID: 32677118
[TBL] [Abstract][Full Text] [Related]
16. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
17. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Kortüm KM; Mai EK; Hanafiah NH; Shi CX; Zhu YX; Bruins L; Barrio S; Jedlowski P; Merz M; Xu J; Stewart RA; Andrulis M; Jauch A; Hillengass J; Goldschmidt H; Bergsagel PL; Braggio E; Stewart AK; Raab MS
Blood; 2016 Sep; 128(9):1226-33. PubMed ID: 27458004
[TBL] [Abstract][Full Text] [Related]
18. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
19. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
Zhou L; Xu G
J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330
[TBL] [Abstract][Full Text] [Related]
20. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]